Lantheus Holdings, Inc.
NASDAQ:LNTH · NASDAQ Global Market
+$1.01 today
Vol 0.99M · Avg 0.94M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $233.6M -25.2% | $312.4M -4.4% | $326.7M +1063.9% | $28.1M +139.4% | -$71.3M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $70.1M +8.5% | $64.6M +7.6% | $60.0M +25.3% | $47.9M +13.3% | $42.3M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $21.6M +187.1% | -$24.8M +55.4% | -$55.6M -9.2% | -$50.9M -1497.1% | $3.6M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $76.4M +51.3% | $50.5M +72.6% | $29.3M +83.6% | $15.9M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$44.2M -2259.9% | $2.0M +101.2% | -$171.2M -128.1% | -$75.1M -395.3% | -$15.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$17.9M +52.5% | -$37.7M +45.1% | -$68.6M +46.6% | -$128.5M -288.1% | -$33.1M | $592.6M | $1.3B | $626.2M |
| Inventory | -$9.4M -250.8% | -$2.7M +92.6% | -$36.2M -382.4% | -$7.5M -111.6% | -$3.5M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$2.5M +71.7% | -$8.8M -151.2% | $17.2M +5610.6% | $301.0K -94.5% | $5.4M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$14.5M -128.3% | $51.2M +161.3% | -$83.5M -237.8% | $60.6M +277.1% | $16.1M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $109.1M -4.3% | $114.0M +20.2% | $94.9M -68.6% | $302.5M +285.5% | $78.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $390.1M -28.4% | $544.8M +78.5% | $305.3M +8.3% | $281.8M +422.6% | $53.9M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$36.1M +30.1% | -$51.6M -10.9% | -$46.6M -153.7% | -$18.3M -51.1% | -$12.1M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$575.7M -611.5% | -$80.9M | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$10.0M +88.0% | -$83.2M | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 -100.0% | $17.8M -66.2% | $52.5M +120.3% | -$258.2M -1731.8% | $15.8M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$627.2M -177.5% | -$226.0M -3905.6% | $5.9M +102.1% | -$276.5M -7608.7% | $3.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$1.1M -249.1% | -$318.0K +55.6% | -$717.0K -100.2% | $382.4M +982.1% | -$43.3M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $10.9M +215.4% | $3.5M +78.5% | $1.9M +40.6% | $1.4M +79.3% | $767.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$300.0M -200.0% | -$100.0M | $0 +100.0% | -$75.0M | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$26.3M -21.6% | -$21.7M -51.8% | -$14.3M -583.8% | $3.0M -9.2% | $3.2M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$316.6M -167.1% | -$118.5M -807.5% | -$13.1M -104.2% | $311.7M +892.5% | -$39.3M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$49.0K +95.1% | -$998.0K -973.1% | -$93.0K +72.2% | -$335.0K -8.1% | -$310.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$553.7M -377.9% | $199.2M -33.2% | $298.0M -5.9% | $316.6M +1663.0% | $18.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $354.1M -28.2% | $493.1M +90.6% | $258.7M -1.8% | $263.4M +530.6% | $41.8M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$6.03B
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
$5.25B
Hinge Health, Inc.
NYSE:HNGE
$5.20B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.83B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.81B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.71B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.55B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.97B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.82B
Bausch Health Companies Inc.
NYSE:BHC
$1.75B
SEC Filings
Recent regulatory filings
No filings found.
Does LNTH generate free cash flow?
Lantheus Holdings, Inc. (LNTH) generated $354.05M of free cash flow in fiscal 2025.
How much operating cash flow does LNTH produce?
Operating cash flow was $390.14M, before capital expenditures of $36.09M.
Explore More
Continue the stock analysis
Jump to another research area for this company.